Incyte PORTFOLIO

Targeted Therapy

Clinical Proof Discovery Pivotal Marketed of Concept

Jakafi® (ruxolitinib)1 JAK1/JAK2 Myelofibrosis2 United States

Jakafi® (ruxolitinib)1 JAK1/JAK2 Polycythemia vera3 United States

Iclusig® (ponatinib)4 BCR-ABL CML, Ph+ ALL Europe

Ruxolitinib JAK1/JAK2 Acute graft-versus-host disease

Ruxolitinib JAK1/JAK2 Chronic graft-versus-host disease

JAK1/JAK2

JAK1

Itacitinib JAK1 Chronic graft-versus-host disease

5 JAK1 Non-small cell lung cancer

Pemigatinib FGFR1/2/3 Bladder cancer

Pemigatinib FGFR1/2/3 Cholangiocarcinoma

Pemigatinib FGFR1/2/3 8p11 MPN

Targeted Therapy

Clinical Proof Discovery Pivotal Marketed of Concept

INCB50465 PI3Kδ Follicular lymphoma

INCB50465 PI3Kδ Marginal zone lymphoma

INCB50465 PI3Kδ Mantle cell lymphoma

INCB53914 PIM Advanced malignancies

INCB59872 LSD1 AML, small cell lung cancer

INCB62079 FGFR4 Liver cancer

Immuno-Therapy

Clinical Proof Discovery Pivotal Marketed of Concept

Epacadostat6 IDO1 Non-small cell lung cancer (with pembrolizumab)

Epacadostat IDO1

INCB011587 ARG Solid tumors

Immuno-Therapy

Clinical Proof Discovery Pivotal Marketed of Concept

INCMGA00128 PD-1 MSI-H endometrial cancer

INCMGA00128 PD-1 Markel cell carcinoma

INCMGA00128 PD-1 Anal cancer

INCAGN18769 GITR Solid tumors

INCAGN19499 OX40 Solid tumors

INCAGN23909 TIM-3 Solid tumors

INCAGN23859 LAG-3 Solid tumors

INCB81776 AXL/MER Solid tumors

Inflammation/Autoimmunity

Clinical Proof Discovery Pivotal Marketed of Concept

Ruxolitinib cream JAK1/JAK2 Atopic dermatitis

Inflammation/Autoimmunity

Clinical Proof Discovery Pivotal Marketed of Concept

Ruxolitinib cream JAK1/JAK2 Vitiligo

INCB54707 JAK1 Hidradenitis suppurativa

Partnered

Clinical Proof Discovery Pivotal Marketed of Concept

Olumiant® (baricitinib)10 JAK1/JAK2 Rheumatoid arthritis

Baricitinib10 JAK1/JAK2 Psoriatic arthritis

Baricitinib10 JAK1/JAK2 Atopic dermatitis

Baricitinib10 JAK1/JAK2 Systemic lupus erythematosus

Baricitinib10 JAK1/JAK2 Alopecia areata

Capmatinib11 MET Non-small cell lung cancer

Capmatinib11 MET Liver cancer

Updated as of October 19, 2018 1. Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US 2. Patients with intermediate or high-risk myelofibrosis 3. Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. European rights to Iclusig licensed from ARIAD 5. In collaboration with AstraZeneca 6. In collaboration with Merck 7. Co-development with Calithera 8. In collaboration with MacroGenics 9. Discovery alliance with Agenus 10. Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 11. Worldwide rights to capmatinib licensed to Novartis